Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M011
- Development stage
- Preclinical
- Modality
- Peptides
- Administration
- Oral
01
Overview
M011 is a cell-permeable stapled peptide designed to bind with high affinity to Mdm2, a primary antagonist of the p53 tumor suppressor. This binding leads to the activation of p53, making M011 a potential therapeutic agent for cancer. Its structure includes a non-natural L-6-chlorotryptophan residue, which contributes to its improved affinity.
02
Targets
MDM2 (Mouse double minute 2 homolog)MDM4 (Mouse double minute X homolog)
Beyond the preview
Go deeper on M011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M011.